This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C07 | Special Copayment Reduction: V193 (5% copayment for treatment of the relevant condition for 5 years from the date of cancer patient registration) |
| B. Synonyms | Parotid cancer, parotid gland cancer, malignant tumor of the parotid; Parotid gland carcinoma, Malignant parotid tumor, Parotid cancer |
| C. Adult onset | Likelihood of first onset in adulthood: very high — mean age at diagnosis about 61 years; mucoepidermoid carcinoma in the 40s–60s, adenoid cystic carcinoma in the 40s–70s |
| 1. History | Parotidectomy systematized in the 19th century; histologic classification, facial nerve preservation and radiotherapy introduced in the 20th century; WHO classification continually updated |
| 2. Causes | Radiation exposure (established risk factor), malignant transformation of pleomorphic adenoma, occupational carcinogen exposure, smoking (some histologic types), EBV and HPV (some cases) |
| 3. Genetics | Mucoepidermoid carcinoma: MAML2 rearrangement; adenoid cystic carcinoma: MYB-NFIB fusion; carcinoma ex pleomorphic adenoma: HMGA2 and PLAG1; research on EGFR, HER2 and FGFR targets |
| 4. General epidemiology | 1–3% of all head and neck cancers; about 70% of major salivary gland malignancies arise in the parotid; about 0.5–1 case per million population; nearly equal in men and women |
| 5. Pathophysiology | Multistep carcinogenesis of salivary duct epithelium or acinar cells; histotype-specific molecular mechanisms (MAML2, MYB-NFIB); malignant transformation of pleomorphic adenoma |
| 6. Symptoms | Painless mass in the parotid region (early), facial nerve palsy (specific sign of malignancy), pain, skin fixation and neck mass (advanced) |
| 7. Signs | Hard mass in the parotid region, facial nerve palsy (marginal mandibular branch or entire nerve), enlarged lymph nodes in neck levels II, III and V, high uptake on PET-CT |
| 8. Screening | Physical examination of the parotid region, head and neck ultrasound, regular follow-up of high-risk groups (people exposed to radiation, patients with pleomorphic adenoma) |
| 9. Diagnosis | Ultrasound, MRI, CT, PET-CT; fine-needle aspiration cytology (FNAC) and core biopsy; histopathology (WHO 2022 classification); AJCC 8th edition staging |
| 10. Treatment | Surgery (parotidectomy + facial nerve preservation/sacrifice), adjuvant radiotherapy (high dose, especially for ACC and high-grade tumors), chemotherapy (cisplatin, carboplatin, taxane), HER2-targeted therapy (lapatinib, trastuzumab), immunotherapy |
| 11. Prognosis | 5-year survival 68%, 10-year 45%; histologic grade, stage, facial nerve involvement and lymph node metastasis are the key prognostic factors; ACC: late-onset distant metastasis |
| 12. Prevention | Minimize unnecessary head and neck radiation exposure, manage occupational carcinogens, long-term follow-up of pleomorphic adenoma, regular physical examination |
| 13. References | Parotid Cancer - StatPearls (NCBI, 2024) ... and 9 other papers |
Malignant neoplasm of the parotid gland is the most common malignancy among salivary gland tumors and has historically posed unique challenges in diagnosis and treatment. This is because, owing to the anatomic course of the facial nerve (CN VII) through the parotid gland, facial nerve injury during surgery has been a major source of morbidity.
In the early 19th century, European surgeons attempted surgical excision of parotid tumors, but techniques for identifying and preserving the facial nerve were systematized only in the 20th century. The modern prototype of parotidectomy that identifies and preserves the facial nerve was established in the 1930s–1940s, and Janes (1940) described a procedure that resects even the deep lobe of the parotid while preserving the facial nerve.
In the mid-20th century, a systematic pathologic classification of the various histologic types of salivary gland tumors was developed. The WHO classification of salivary gland tumors has been revised several times since 1972, and the 2022 WHO 5th edition added many new histologic types based on molecular pathologic features. Carcinoma ex pleomorphic adenoma (CExPA), the malignant transformation of pleomorphic adenoma, was established as an important histologic type.
Radiotherapy has been established as standard adjuvant treatment for parotid cancer since the 1970s. The role of high-dose radiotherapy and proton therapy has been studied particularly for adenoid cystic carcinoma (ACC), which shows marked perineural invasion. In the 21st century, clinical application of molecular targeted therapy (trastuzumab in HER2-positive parotid cancer) and immune checkpoint inhibitors is being investigated.
Unlike other head and neck squamous cell carcinomas, in parotid cancer radiation exposure and the intrinsic carcinogenic mechanisms of specific histologic types are more important causes than smoking and alcohol.
Exposure to ionizing radiation is the best-established environmental risk factor for parotid cancer. An increased risk of parotid cancer has been confirmed in people with a history of head and neck radiotherapy, radioactive iodine (I-131) therapy, and in studies of survivors of the Hiroshima and Nagasaki atomic bombings. Head and neck irradiation in childhood also increases the long-term risk of parotid cancer.
Malignant transformation of a long-neglected pleomorphic adenoma is an important pathway in the development of parotid cancer. The rate of malignant change of pleomorphic adenoma rises to about 1–5% when left untreated for 10 years or more, and the resulting carcinoma ex pleomorphic adenoma (CExPA) is a high-grade malignancy.
Occupational exposure to aromatic compounds, asbestos, metal dust and wood dust has been associated with an increased risk of parotid cancer in some studies. EBV (Epstein-Barr virus) is associated with lymphoepithelial carcinoma of the parotid. Smoking is associated with some histologic types of parotid tumor (related to Warthin tumor), but it is not as strong a risk factor as in squamous cell carcinoma.
Parotid cancer shows histotype-specific patterns of molecular genetic alterations, which form the molecular biological basis of the WHO classification.
MEC, the most common malignancy of the parotid gland, is characterized by MAML2 gene rearrangement (CRTC1-MAML2 or CRTC3-MAML2 fusion, 11q21-q23 translocation). MAML2 rearrangement positivity is associated with low- to intermediate-grade MEC and suggests a better prognosis. High-grade MEC lacks MAML2 rearrangement and shows TP53 mutations and EGFR overexpression.
The MYB-NFIB gene fusion (t(6;9)) is the characteristic alteration found in 75–90% of ACC; overexpression of the MYB transcription factor promotes tumor proliferation. NOTCH1/2 mutations (about 15%) and KIT overexpression are also observed. ACC shows very strong perineural invasion and tends to develop late distant metastasis (especially to the lungs).
Rearrangements of the HMGA2 and PLAG1 genes are found in both pleomorphic adenoma and CExPA, suggesting origin from a pleomorphic adenoma precursor. TP53 mutations and EGFR amplification are added during malignant transformation.
EGFR overexpression in parotid squamous cell carcinoma and HER2 (ERBB2) amplification in some parotid cancers (especially secretory carcinoma, salivary duct carcinoma) have been identified, providing the basis for studies of HER2-targeted therapies such as trastuzumab and lapatinib. Alterations in the FGFR pathway are also being explored. PD-L1 CPS and TMB are used to determine eligibility for immune checkpoint inhibitors.
Parotid cancer is a relatively rare cancer, accounting for about 1–3% of all head and neck malignancies. Among malignancies of the major salivary glands (parotid, submandibular, sublingual), about 70% arise in the parotid, the largest share.
The incidence of parotid malignancy is low, about 0.5–1 case per million population. About 55,000 salivary gland tumors occur worldwide each year, of which parotid cancer accounts for a large share. In Korea, parotid cancer is often counted together with all salivary gland cancers rather than reported separately, and it is included within the rising trend of head and neck tumors overall. An analysis of head and neck cancer trends in Korea from 1999 to 2012 reported a rising incidence of major salivary gland cancer (including the parotid).
Parotid cancer occurs almost equally in men and women, but this varies by histologic type. Mucoepidermoid carcinoma is somewhat more common in women. The mean age at diagnosis is about 61 years, varying by histologic type. Adenoid cystic carcinoma also commonly occurs at relatively young ages, in the 40s–60s.
The pathogenesis of parotid cancer differs fundamentally by histologic type; unlike squamous cell carcinoma, most are differentiated carcinomas originating from the salivary duct epithelium or acinar cells.
In the multistep carcinogenesis of salivary duct epithelium, the CRTC1-MAML2 gene fusion causes overexpression of an EGFR ligand (amphiregulin), promoting cell proliferation. Low-grade MEC is driven by a single oncogenic pathway due to this fusion gene, whereas high-grade MEC acquires additional TP53 mutations and EGFR overexpression.
The MYB-NFIB fusion protein causes overexpression of the MYB transcription factor, which promotes cell proliferation, survival and differentiation. ACC shows three growth patterns — tubular, cribriform and solid — of which the solid pattern is the most aggressive. Perineural invasion is explained by interactions between neurotrophic factors (BDNF, NT-3) and the c-Ret receptor.
In pleomorphic adenoma, HMGA2 and PLAG1 rearrangements contribute to early carcinogenesis, and malignant transformation to CExPA then occurs as TP53 mutations, EGFR amplification and chromosomal instability accumulate. CExPA appears as a high-grade adenocarcinoma or dysplastic differentiated carcinoma component arising within the stroma of a pleomorphic adenoma.
In the clinical presentation of parotid cancer, differentiation from benign parotid tumors (especially pleomorphic adenoma) is important, and attention should be paid to specific symptoms suggesting malignancy.
The most common early symptom is a slowly enlarging painless mass in the parotid region. This symptom alone is difficult to distinguish from a benign tumor; when a mass that has persisted unchanged in size for years suddenly enlarges, malignant transformation of a pleomorphic adenoma should be suspected. A mass with an irregular surface, ill-defined borders and adhesion to surrounding tissue strongly suggests malignancy.
Facial nerve palsy is the most important clinical finding strongly suggesting malignancy in a parotid tumor. Facial nerve palsy may initially involve only one branch and extend to all branches as it progresses. Facial asymmetry, difficulty closing the eye and drooping of one side of the mouth appear. Otalgia, skin fixation over the parotid region and a neck mass also suggest malignancy.
As the tumor invades adjacent structures, trismus (pterygoid muscle invasion), dysphagia, and invasion of the auricle or external auditory canal occur. Distant metastasis (especially lung metastasis of ACC) may develop without symptoms, with respiratory symptoms appearing only later.
A hard mass with irregular borders is palpable in the parotid region. Adhesion to surrounding tissue and skin fixation are signs of malignancy. Facial nerve palsy is a specific sign of a malignant parotid tumor and shows a peripheral facial nerve palsy pattern. Lymph node metastasis from the parotid region to neck levels II and III (upper neck) and level V (spinal accessory lymph nodes) is observed.
Ultrasound shows hypoechogenicity, irregular borders and increased blood flow. On MRI it appears as an irregular, enhancing mass, and the extent of invasion of facial nerve–related structures is assessed. CT is useful for evaluating lymph node metastasis and jaw bone invasion. PET-CT is used to evaluate distant metastasis in high-grade malignancies, but low-grade distant metastases of ACC may be falsely negative on PET-CT.
There is no systematic national screening program for parotid cancer, but physical examination in high-risk groups contributes to early detection.
Palpation of the parotid region during regular head and neck physical examination is the basis of screening. Head and neck ultrasound is the first-line imaging tool for detecting parotid masses and differentiating benign from malignant. A parotid mass accompanied by facial nerve palsy requires immediate MRI and biopsy.
Regular physical examination and ultrasound follow-up are recommended for people with a history of head and neck radiotherapy, people with a history of radioactive iodine therapy, and patients under follow-up after a diagnosis of pleomorphic adenoma. Pleomorphic adenoma rarely recurs even after complete excision, and because a long-neglected pleomorphic adenoma carries a risk of malignant transformation, complete excision is recommended.
Ultrasound: used for initial evaluation of parotid masses and for guiding fine-needle aspiration cytology (FNAC). MRI: the standard imaging test for parotid cancer, precisely evaluating deep lobe involvement, invasion of facial nerve–related structures, skull base invasion and perineural spread (cranial nerve perineural spread). CT: useful for evaluating cervical lymph node metastasis and jaw bone invasion. PET-CT: used to evaluate distant metastasis of high-grade malignancies. Chest CT follow-up is essential for ACC patients.
Fine-needle aspiration cytology (FNAC) is used for initial cytologic evaluation of parotid masses, but cytologic classification is difficult because of the diversity of histologic types of salivary gland tumors. Definitive diagnosis requires core needle biopsy or final pathologic diagnosis after surgical excision. The histologic type (mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma NOS, secretory carcinoma, others) is confirmed according to the WHO 2022 classification. Immunohistochemistry: MAML2 FISH, MYB expression, HER2, EGFR, Ki-67 and TP53 staining are used as adjuncts.
T classification of parotid cancer: T1 (≤2 cm, no extraparenchymal extension), T2 (>2–4 cm), T3 (>4 cm or extraparenchymal extension), T4a (invasion of skin, mandible, external auditory canal or facial nerve), T4b (invasion of skull base, pterygoid plates or internal carotid artery). N classification is determined by size, number, laterality and ENE.
Parotidectomy is the primary standard treatment for parotid cancer. Superficial parotidectomy is performed when the tumor is confined to the superficial lobe of the parotid, and total parotidectomy when the deep lobe is involved. If the tumor does not invade the facial nerve, preservation of the facial nerve is the rule, but if the nerve is invaded, nerve grafting (cable graft) is performed after resection. Facial rehabilitation (suture repair, nerve reconstruction) after facial nerve resection is also planned. Ipsilateral selective neck dissection is performed concurrently.
Adjuvant IMRT (60–66 Gy or more) is given when high-risk features are present (T3-T4, positive margins, perineural invasion, lymph node metastasis, ENE, high grade). In ACC, because perineural invasion is common, the radiation field is extended to the skull base. Proton therapy is used in some patients because it is advantageous for protecting structures around the skull base.
Cisplatin-, carboplatin- and taxane-based chemotherapy is used for recurrent or metastatic parotid cancer. In HER2-positive disease (secretory carcinoma, some adenocarcinomas), the efficacy of targeted therapy with trastuzumab and lapatinib has been reported in some studies. When an NTRK fusion is present (some secretory carcinomas), larotrectinib is effective. Immune checkpoint inhibitors (pembrolizumab, nivolumab) are used in patients selected by biomarkers such as CPS and TMB.
The prognosis of parotid cancer is largely determined by histologic type, grade, stage and facial nerve involvement.
For parotid malignancies, the 5-year overall survival rate is about 68% and the 10-year survival rate is about 45%. Low-grade mucoepidermoid carcinoma and acinic cell carcinoma have a favorable 5-year survival rate of 80–90% or higher. High-grade MEC, high-grade adenoid cystic carcinoma (solid type), CExPA and adenocarcinoma NOS have a poor prognosis, with 5-year survival rates of about 30–50%.
| Prognostic factors | Effect |
|---|---|
| Histologic grade (low, intermediate, high) | Most important prognostic factor |
| T stage (size >4 cm) | Poor prognosis |
| Facial nerve involvement | Poor prognosis, increased recurrence rate |
| Cervical lymph node metastasis | Survival reduced by 50% or more |
| Extranodal extension (ENE) | Independent poor prognostic factor |
| Distant metastasis | Median survival about 3 years |
Because ACC can develop distant metastasis (mainly to the lungs) even 10–15 years later, long-term follow-up is essential. Even with lung metastases, the slow growth rate may allow the patient to remain asymptomatic for years, and in selected cases long-term survival is possible with resection of lung metastases.
Minimizing unnecessary head and neck radiation exposure is the most important means of prevention. Lead shielding during dental radiography, appropriate dose management for diagnostic radiation, and minimizing parotid dose during head and neck radiotherapy (using IMRT) are needed. Management of and protection from occupational radiation exposure (e.g., nuclear-related occupations) are needed.
When a painless mass is found in the parotid region, immediate physical examination and ultrasound are performed. Complete excision of pleomorphic adenoma is key to preventing long-term malignant transformation. Regular examination of the parotid region and ultrasound follow-up are recommended for people with a history of radiotherapy or radioactive iodine therapy. A parotid mass accompanied by facial nerve palsy requires urgent evaluation and treatment.
Mendenhall WM, Riggs CE Jr, Vaysberg M, et al. Parotid Cancer - StatPearls. NCBI Bookshelf. 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538340/
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org
Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7
Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period. Cancers. 2022;14(17):4190. DOI: 10.3390/cancers14174190
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834
Park JO, Joo YH, Jung CK, et al. Trends in Head and Neck Cancer in South Korea Between 1999 and 2012. JAMA Otolaryngology–Head & Neck Surgery. 2016;142(12):1157-1165. DOI: 10.1001/jamaoto.2016.2396
An overview of the rare parotid gland cancer. Head & Neck Oncology. 2011;3:40. DOI: 10.1186/1758-3284-3-40
WHO Classification of Tumours Editorial Board. Head and Neck Tumours, WHO Classification of Tumours, 5th Ed. IARC Press. Lyon, 2022. ISBN: 978-92-832-4518-7.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. DOI: 10.3322/caac.21763